Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation
about
Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancerCirculating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancerMesothelin targeted cancer immunotherapyAdvances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancerMolecular therapeutics in pancreas cancerFrom bench to bedside a comprehensive review of pancreatic cancer immunotherapy.Viro-immune therapy: A new strategy for treatment of pancreatic cancerCancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reactionFueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitorsImmunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trialsNovel adjuvant therapies for pancreatic adenocarcinomaVaccines for pancreatic cancerCurrent advances in immunotherapy for pancreatic cancerAllogeneic tumor cell vaccines: the promise and limitations in clinical trialsCD40 immunotherapy for pancreatic cancerInflammatory networks and immune surveillance of pancreatic carcinomaRole of α-gal epitope/anti-Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancerThe pancreas cancer microenvironmentAntigen-specific immunotherapy of cervical and ovarian cancerExploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarraysTyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancerCD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humansAutophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy.Discovery of novel tumor markers of pancreatic cancer using global gene expression technology.Re-adapting T cells for cancer therapy: from mouse models to clinical trials.Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical modelMesothelin Immunotherapy for Cancer: Ready for Prime Time?Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulationAllogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.Biological approaches to therapy of pancreatic cancer.Chemoimmunotherapy.Advances in gene therapy for malignant melanoma.Role of GM-CSF signaling in cell-based tumor immunization.Use of tumour-responsive T cells as cancer treatment.Investigational approaches for mesothelioma.Gene therapy in pancreatic cancer.A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer.Progress on new vaccine strategies for the immunotherapy and prevention of cancer.Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survivalEvaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.
P2860
Q24622837-D2C2A6E6-DB9A-48DB-92A8-8E1E464FA06DQ24651062-E7A65D79-DF51-4C55-AC66-9E0D6FE34D94Q24656242-207E7EC3-D772-426A-BC37-00F8D48FC027Q26749451-54260D87-5E5D-461C-BA90-5581F6EC979FQ26751709-2C3131D8-2DE5-4C27-8A48-C8B16D8D026EQ26765123-D6D8FFC3-EB89-44DE-B72A-349A871660E1Q26774641-6A296D8A-7571-4625-8E8E-6FF3B08608A1Q26777542-B63F7677-211C-4183-9C27-7B4868985F44Q26778793-FE810F25-D34F-411D-A6F4-204CEBD8076CQ26781538-D6455D5D-B8A9-4F45-A442-ECF1F3D77258Q26799425-D426436B-4C3E-4ED6-91AE-22133DDFC290Q26825850-97E87581-DE7F-42ED-80C1-5626BBC97476Q26830170-5BE1E492-23B6-4127-9BFD-D03ED452C041Q26852333-20778D85-7212-4787-8521-057E36400C81Q27012550-ACD923E4-FC0C-45DB-9E7B-508CEFA8D6EDQ27013983-32397F1F-5955-4A46-97FE-466C278DEBFCQ27024368-0ADC7C5F-0E39-4551-8B68-A70E4CCCD84DQ27026705-538DD19C-CE60-40C1-925D-D0724CD7FD97Q27488697-EB0C2CAD-4B0D-4206-8FCC-2ABE351ACFA6Q28185685-81148035-3D89-461A-BB44-04D24216C8A9Q28740545-62D308E0-E1E1-49EA-9CC6-E4F8A0CEBF3CQ29614348-B71E1D6C-36EF-45EC-A3FA-1EF12B0EA291Q30402590-EADF6F54-AF98-482A-A4B1-BA9665E822A3Q31048088-33FC62E2-F535-4703-A770-A20460309676Q33588711-1B7810E2-AA47-4460-BA8A-BD1959EF32B3Q33728672-330FA04F-DA28-4594-8108-C7CBAE86EF1BQ33816551-8D5D7A6C-4BBE-4933-ACDB-EEEB698CE1FEQ33848077-61280A36-A386-42C5-BA6F-981FAB0BBCFDQ33887648-610AA579-F375-401A-9CD6-917DBE0D0E16Q33899938-B09D4C1E-DEEE-46F9-BE3E-0669EED19C18Q34058792-5D02548A-ECBF-4522-B723-475AE8F42949Q34119859-655BD7B6-A991-45C2-B4AD-B1C1D8B5BA64Q34147010-DEDE0BAD-96C1-441D-B666-0DB6C273A1B6Q34285656-647DECE1-5106-46D0-919C-7D572BF947C6Q34293068-5F2D957A-63AA-41CE-A937-0C8C9239F912Q34302954-8D847260-0049-4BBB-AFD6-C661D36455F1Q34315863-C76DD120-3C36-499E-BAC5-6D9667AD9BAAQ34328457-7F62B019-6F6C-4C5C-9557-BA08BBDDB626Q34353251-86D2BBA2-8344-49CF-9EB1-8C6825BCB268Q34362516-22A11DD0-3348-4B7F-B0BB-4D7C3B40863C
P2860
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation
description
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2001
@ast
im Januar 2001 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 2001)
@en
vedecký článok (publikovaný 2001/01/01)
@sk
vědecký článek publikovaný v roce 2001
@cs
wetenschappelijk artikel (gepubliceerd op 2001/01/01)
@nl
наукова стаття, опублікована в січні 2001
@uk
مقالة علمية (نشرت عام 2001)
@ar
name
Novel allogeneic granulocyte-m ...... f safety and immune activation
@ast
Novel allogeneic granulocyte-m ...... f safety and immune activation
@en
Novel allogeneic granulocyte-m ...... f safety and immune activation
@nl
type
label
Novel allogeneic granulocyte-m ...... f safety and immune activation
@ast
Novel allogeneic granulocyte-m ...... f safety and immune activation
@en
Novel allogeneic granulocyte-m ...... f safety and immune activation
@nl
prefLabel
Novel allogeneic granulocyte-m ...... f safety and immune activation
@ast
Novel allogeneic granulocyte-m ...... f safety and immune activation
@en
Novel allogeneic granulocyte-m ...... f safety and immune activation
@nl
P2093
P1476
Novel allogeneic granulocyte-m ...... f safety and immune activation
@en
P2093
B Biedrzycki
D M Pardoll
E M Jaffee
J L Cameron
K D Lillemoe
K Schepers
P304
P356
10.1200/JCO.2001.19.1.145
P407
P577
2001-01-01T00:00:00Z